Results 241 to 250 of about 238,930 (305)

Reprogramming the Immune Landscape of Inflammatory Breast Cancer

Advanced Science, EarlyView.
Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez, Suguru Ogata, Xiaoping Wang, Naoto T. Ueno   +3 more
wiley   +1 more source

NAMPT inhibition induces ferroptosis via mitochondrial metabolic reprogramming to enhance tumour immunogenicity in glioblastoma. [PDF]

Front Immunol
Zhao D, Duan L, Ren H, Zhang H, Zhang M, Liu Z, Wang H, Lu W, Shi W, Hou Q, Li T, Li M.   +11 more
europepmc   +1 more source

Senescent Cell Derived Artificial Vesicle‐Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross‐Presentation Efficacy

Advanced Science, EarlyView.
A senolytic sonovaccine platform (SenoVac) is developed, in which senescent cell‐derived vesicles serve as broad senescent cell antigen reservior. The “2‐step” click chemistry strategy for effective lymph node delivery, and ultrasound‐triggered endosomal escape to boost cross‐presentation, ensures efficient senescent cell clearance and disease ...
Liang Zhang, Yubo Lai, Jia Wang, Lingling Liu, Jieyuan An, Mi Qu, Yuan Liang, Bijun Tan, Guodong Yang, Xuekang Yang, Lijun Yuan   +10 more
wiley   +1 more source

Immunogenicity of <i>Theileria parva</i> p67C Antigen Delivered via Adjuvanted CoPoP Liposomes in Cattle and Mice. [PDF]

Vaccines (Basel)
Oboge H, Huang WC, Aboge G, Chege H, Ojuok R, Chege N, Musando J, Poole EJ, Thumbi SM, Nene V, Lovell JF, Lacasta A.   +11 more
europepmc   +1 more source

(Taiwan Journal of Veterinary Medicine and Animal Husbandry 2005 Spring Symposia Taichung,p058)The Immunogenicity of Expressed Glycoprotein E2 of Different Phylogenetic Classical Swine Fever Virus (CSFV)

, 2014
C. W. Wang, Z. W. Chen, S. L. Hsuan, W. C. Lee, M.-S. Chien, C. J. Huang   +5 more
core  

A Humanized Anti‐gD Broadly Neutralizing Antibody Confers Complete Post‐Exposure Protection against Pseudorabies Virus

Advanced Science, EarlyView.
Pseudorabies virus (PRV), an emerging zoonotic α‐herpesvirus, causes life‐threatening human encephalitis. We identified a broad‐spectrum neutralizing antibody 6F7 targeting PRV gD. It blocks gD‐Nectin‐1 binding and membrane fusion, inhibiting replication across all PRV variants, representing a promising candidate for anti‐PRV therapy.
Yue Sun, Jianbo Liu, Shi‐Jia Xu, Meng‐Xin Wang, Hongliang Zhang, Yanhe Zhang, Zhi‐Jun Tian, Jin‐Mei Peng, Xin Yin, Tong‐Qing An, Xue‐Hui Cai, Yan‐Dong Tang   +11 more
wiley   +1 more source

Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b Study. [PDF]

Vaccines (Basel)
Jones JC, Tipton MD, Zolotas L, Maguire JD, Belanger K, Liu Y, Maansson R, O'Neill RE, Balmer P, Peyrani P, Beeslaar J.   +10 more
europepmc   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Design principles of the cytotoxic CD8⁺ T cell response. [PDF]

Proc Natl Acad Sci U S A
Ukogu OA, Montague Z, Altan-Bonnet G, Nourmohammad A.   +3 more
europepmc   +1 more source

Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years. [PDF]

Clin Infect Dis
Goswami J, Cardona JF, Caso J, Hsu DC, Simorellis AK, Wilson L, Dhar R, Wang X, Kapoor A, Collins A, Righi V, Lan L, Du J, Zhou H, Stoszek SK, Shaw CA, Reuter C, Wilson E, Das R.   +18 more
europepmc   +1 more source